Posted by Michael Wonder on 27 Oct 2022
Myeloid Therapeutics announces FDA fast track designation for MT-101 for the treatment of CD5 positive relapsed/refractory PTCL
27 October 2022 - MT-101 is the first mRNA engineered CAR monocyte therapy to be dosed in humans.
Myeloid Therapeutics today announced that the US FDA has granted fast track designation to MT-101 in patients with refractory or relapsed CD5 positive peripheral T cell lymphoma.
